Clicky

Sana Biotechnology, Inc.(SANA)

Description: Sana Biotechnology, Inc. develops and delivers engineered cells as medicine for patients. It identifies and develops potential product candidates; and executes preclinical studies. The company develops technologies to repair and control genes in cells; and replace any cell in the body. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was founded in 2018 and is based in Seattle, Washington with additional offices in South San Francisco, California; and Cambridge, Massachusetts.


Keywords: Biotechnology

Home Page: www.sana.com

SANA Technical Analysis

188 East Blaine Street
Seattle, WA 98102
United States
Phone: 206 701 7914


Officers

Name Title
Dr. Steven D. Harr M.D. Pres, CEO & Director
Dr. Richard C. Mulligan Ph.D. Exec. Vice Chairman & Head of SanaX
Mr. Nathan Hardy M.B.A. Exec. VP & CFO
Dr. Sunil Agarwal M.D. Exec. VP, Head of Devel. & Chief Medical Officer
Ms. Shanna Clouse Peek Sr. VP & Head of Corp. Operations
Brittany Mccleery Accounting Mang.
Dr. Edward Rebar Ph.D. Sr. VP & CTO
Mr. Bernard J. Cassidy J.D. Exec. VP & Gen. Counsel
Ms. Robin Andrulevich Exec. VP & Chief People Officer
Mr. Paul Brunetta M.D. Sr. VP and Head of Clinical & Translational Science

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.3917
Price-to-Sales TTM: 0
IPO Date: 2021-02-04
Fiscal Year End: December
Full Time Employees: 494
Back to stocks